Literature DB >> 17189960

Molecular therapy in the microRNA era.

T Wurdinger1, F F Costa.   

Abstract

MicroRNAs (miRNAs) consist of a growing class of non-coding RNAs (ncRNAs) that negatively regulate the expression of genes involved in development, differentiation, proliferation, apoptosis and other important cellular processes. miRNAs are usually 18-25 nt long and are each able to regulate several mRNAs by mechanisms such as incomplete base pairing and Post-Transcriptional Gene Silencing (PTGS). A growing number of reports have shown that aberrant miRNA expression is a common feature of human diseases including cancer, which has sparked interest in targeting these regulators of gene expression as a means of ameliorating these diseases. Here, we review important aspects of miRNA function in normal and pathological states and discuss new modalities of epigenetic intervention strategies that could be used to amend defects in miRNA/mRNA interactions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17189960     DOI: 10.1038/sj.tpj.6500429

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  32 in total

Review 1.  Cancer epigenetics: above and beyond.

Authors:  Mariana Brait; David Sidransky
Journal:  Toxicol Mech Methods       Date:  2011-05       Impact factor: 2.987

2.  Ectopic expression of miR-494 inhibited the proliferation, invasion and chemoresistance of pancreatic cancer by regulating SIRT1 and c-Myc.

Authors:  Y Liu; X Li; S Zhu; J-g Zhang; M Yang; Q Qin; S-c Deng; B Wang; K Tian; L Liu; Y Niu; C-y Wang; G Zhao
Journal:  Gene Ther       Date:  2015-04-28       Impact factor: 5.250

Review 3.  MicroRNAs and ultraconserved genes as diagnostic markers and therapeutic targets in cancer and cardiovascular diseases.

Authors:  Julianna K Edwards; Renata Pasqualini; Wadih Arap; George A Calin
Journal:  J Cardiovasc Transl Res       Date:  2010-05-05       Impact factor: 4.132

4.  Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma.

Authors:  Carmit Levy; Mehdi Khaled; Dimitrios Iliopoulos; Maja M Janas; Steffen Schubert; Sophie Pinner; Po-Hao Chen; Shuqiang Li; Anne L Fletcher; Satoru Yokoyama; Kenneth L Scott; Levi A Garraway; Jun S Song; Scott R Granter; Shannon J Turley; David E Fisher; Carl D Novina
Journal:  Mol Cell       Date:  2010-11-25       Impact factor: 17.970

5.  Upregulation of mir-221 and mir-222 in atypical teratoid/rhabdoid tumors: potential therapeutic targets.

Authors:  Simone Treiger Sredni; Maria de Fátima Bonaldo; Fabrício Falconi Costa; Chiang-Ching Huang; Christopher Allan Hamm; Veena Rajaram; Tadanori Tomita; Stewart Goldman; Jared Marshall Bischof; Marcelo Bento Soares
Journal:  Childs Nerv Syst       Date:  2009-12-10       Impact factor: 1.475

6.  MicroRNA reexpression as differentiation therapy in cancer.

Authors:  Prasun J Mishra; Glenn Merlino
Journal:  J Clin Invest       Date:  2009-07-20       Impact factor: 14.808

7.  MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma.

Authors:  Aaron J Schetter; Suet Yi Leung; Jane J Sohn; Krista A Zanetti; Elise D Bowman; Nozomu Yanaihara; Siu Tsan Yuen; Tsun Leung Chan; Dora L W Kwong; Gordon K H Au; Chang-Gong Liu; George A Calin; Carlo M Croce; Curtis C Harris
Journal:  JAMA       Date:  2008-01-30       Impact factor: 56.272

Review 8.  Glioma angiogenesis: Towards novel RNA therapeutics.

Authors:  Thomas Würdinger; Bakhos A Tannous
Journal:  Cell Adh Migr       Date:  2009-04-22       Impact factor: 3.405

9.  miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells.

Authors:  Thomas Würdinger; Bakhos A Tannous; Okay Saydam; Johan Skog; Stephan Grau; Jürgen Soutschek; Ralph Weissleder; Xandra O Breakefield; Anna M Krichevsky
Journal:  Cancer Cell       Date:  2008-11-04       Impact factor: 31.743

10.  MicroRNA: An emerging therapeutic target and intervention tool.

Authors:  Zhen Liu; Alhousseynou Sall; Decheng Yang
Journal:  Int J Mol Sci       Date:  2008-06-13       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.